23 articles - From Friday Aug 26 2022 to Friday Sep 02 2022
Guidelines, position statements, white papers, technical reviews, consensus statements, etc…
| Arthritis Rheumatol |
Management of orofacial manifestations of juvenile idiopathic arthritis: Interdisciplinary consensus-based recommendations. These are the first interdisciplinary recommendations to guide clinical management of TMJ JIA. The 3 overarching principles and 12 recommendations fill an important gap in current clinical practice. They emphasize the importance of an interdisciplinary approach to diagnosis and management of orofacial manifestations of JIA. |
meta-analyses and systematic reviews
RCT, clinical trials, retrospective studies, etc…
| Ann Rheum Dis |
Diagnostic evaluation of the sacroiliac joints for axial spondyloarthritis: should MRI replace radiography? In this viewpoint, we will argue that it is time to replace conventional radiographs with MRI for the assessment of structural changes in sacroiliac joints. This message is based on current data on the following questions: (1) How reliable are conventional radiographs in the diagnosis of axSpA overall and radiographic axSpA in particular? (2) How does T1-weighted MRI compare to radiographs in the detection of sacroiliitis? (3) Are there now other (better) MRI sequences than T1-weighted, which might be more suitable for the detection of structural lesions? (4) Which MRI sequences should be performed for the diagnostic evaluation of the sacroiliac joints? (5) Do we have data to define sacroiliitis based on structural changes detected by MRI? |
| Arthritis Care Res (Hoboken) |
Health-Related Quality of Life in Adults with Adolescent- and Adult-onset Systemic Lupus Erythematosus: A Longitudinal Study of a Multiethnic US Cohort (LUMINA LXXXIV). Adults with adolescent-onset SLE exhibited better physical functioning when compared with the adult SLE group despite more severe disease; noteworthy, HRQoL was below the general US population despite clinically meaningful improvement in HRQoL over time in both groups. |
Hydroxychloroquine and Risk of Long QT Syndrome in Rheumatoid Arthritis: A Veterans Cohort Study with 19-Year Follow-up. Hydroxychloroquine use had no association with LQTS during the first 2 |
Monitoring and achievement of target serum urate among gout patients receiving long-term urate lowering therapy in the ACR's RISE Registry. Among gout patients receiving long-term ULT followed longitudinally by rheumatologists, more than half had a documented SU and among those tested, three quarters achieved the recommended SU target. Routine monitoring of SU is a first step toward improving quality of care for patients with gout. |
Using data-driven approaches to classify and predict healthcare spending in patients with gout using urate-lowering therapy. We identified distinct long-term healthcare spending patterns in patients with gout using ULT with high accuracy. Several clinical predictors could be key areas for intervention, such as gout medication use or diabetes. |
| Arthritis Res Ther |
A multicentre, efficacy and safety study of methotrexate to increase response rates in patients with uncontrolled gout receiving pegloticase (MIRROR): 12-month efficacy, safety, immunogenicity, and pharmacokinetic findings during long-term extension of an open-label study. Pegloticase |
Association between low hemoglobin, clinical measures, and patient-reported outcomes in patients with rheumatoid arthritis: results from post hoc analyses of three phase III trials of sarilumab. In these post hoc analyses, a consistent relationship was observed between higher Hb levels and better clinical outcomes and PROs in patients with RA. Irrespective of the baseline Hb levels, sarilumab treatment was associated with improvements in clinical measures and PROs over 24 weeks (improvements were more pronounced than those with adalimumab treatment) and mitigation of joint damage progression over 52 weeks. |
Baseline IgG-Fc N-glycosylation profile is associated with long-term outcome in a cohort of early inflammatory arthritis patients. Pending confirmation of these findings in larger cohorts, IgG glycosylation levels could be used as a prognostic marker in early arthritis, to overcome the limitations of the current prognostic tools. |
| Rheumatology (Oxford) |
A data-driven approach finds RNA polymerase III antibody and tendon friction rubs as enrichment tools for early diffuse scleroderma trials. Adjustment for both RNAP3 and TFR predicts mRSS trajectory and diminished the mRSS decline in ASSET placebo group, and identified significant differences in CRISS. RNAP3, particularly, is a stratification or enrichment approach to improve early diffuse SSc trial design. |
A panel of plasma microRNAs improves the assessment of surrogate markers of cardiovascular disease in rheumatoid arthritis patients. Plasmatic expression of microRNA-24, 96, 103, 125a, 132, 146, 191, 223 and Let7a were associated with surrogate markers of CV disease and could be predictors of CV risk in patients with RA. |
Allelic expression imbalance in articular cartilage and subchondral bone refined genome-wide association signals in osteoarthritis. By prioritizing proxy transcript SNPs that mark AEI in cartilage and/or subchondral bone at loci harboring GWAS signals, we present an unbiased approach to identify the most likely functional OA risk-SNP and gene. We identified 10 new potential OA risk genes ready for further, translation towards underlying biological mechanisms. |
Impact of initial therapy with upadacitinib or adalimumab on achievement of 48-week treatment goals in patients with rheumatoid arthritis: post hoc analysis of SELECT-COMPARE. Following a modified treat-to-target strategy, rates of CDAI remission/LDA and DAS28(CRP) <2.6/=3.2 at 48 |
Is vaccination against Covid-19 associated with autoimmune rheumatic disease flare? A self-controlled case series analysis. Vaccination against Covid-19 was not associated with increased AIRD flares regardless of prior Covid-19, AIRD type, and whether mRNA or DNA vaccination technology were used. |
Longitudinal global transcriptomic profiling of preclinical systemic sclerosis reveals molecular changes associated with disease progression. Participants with PreSSc had a distinct gene expression profile indicating that molecular differences at a transcriptomic level are already present in the preclinical stages of SSc. Furthermore, a reduced NK signature in PBCs was related to SSc progression over time. |
Sustained glucocorticoid tapering in the phase 3 trials of anifrolumab: a post-hoc analysis of the TULIP-1 and TULIP-2 trials. Sustained glucocorticoid tapering is associated with clinical benefits. Anifrolumab treatment has potential to reduce disease activity and glucocorticoid exposure, a key goal of SLE management. |
Plenty of the editorials are available as full text through the publisher website using the provided link
| Ann Rheum Dis |
misc publications eg case reports, tools of the trade, images of the month, etc…
| Arthritis Rheumatol |
| Rheumatology (Oxford) |
Letters to the editors and authors’ replies